Zelgen Biopharma Unveils Breakthrough Data for Bispecific and Trispecific Antibodies at ASCO 2026
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) presented compelling clinical data at the 2026 American...
Company
Novartis’ Scemblix Demonstrates Sustained Superiority Over Standard TKIs in Chronic Myeloid Leukemia with 144-Week ASC4FIRST Data
Novartis AG (NYSE: NVS) announced compelling long-term efficacy data from the pivotal ASC4FIRST Phase III...
Haisco Pharmaceutical and Eli Lilly Forge $3 Billion Drug Discovery Alliance Spanning Multiple Therapeutic Areas
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) and Eli Lilly and Company (NYSE: LLY) announced...
BMS Secures EC Approval for Opdivo-AVD Combination in Advanced Classical Hodgkin Lymphoma
Bristol-Myers Squibb Co. (BMS, NYSE: BMY) announced that the European Commission (EC) has granted marketing...
D3 Bio’s Next-Gen KRAS G12C Inhibitor Elisrasib Shows 81% Response Rate in First-Line NSCLC at ASCO 2026
D3 Bio, a China-based biotechnology company, presented updated Phase I/II clinical data for elisrasib (D3S-001),...
Impact Therapeutics’ Selective PARP1 Inhibitor IMP1734 Shows 29.6% Response Rate in Ovarian Cancer at ASCO 2026
Impact Therapeutics (HKG: 7630) presented updated Phase I/II clinical data for IMP1734 (EIK1003), a highly...
CTTQ’s EGFR/c-MET Bispecific ADC TQB6411 Shows 44% Response Rate in Heavily Pretreated Solid Tumors at ASCO 2026
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG:...
GenFleet’s GFS202A Becomes World’s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026
GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) presented preliminary Phase I clinical data for GFS202A, the...
LaNova’s CLDN18.2 ADC LM-302 Shows 15-Month PFS in Gastric Cancer Phase II Data at ASCO 2026
LaNova Medicines Ltd., a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented Phase II clinical...
Alphamab-CSPC’s HER2 Bispecific Antibody Anbenitamab Wins NMPA Approval for Refractory Gastric Cancer with 75% PFS Benefit
China’s National Medical Products Administration (NMPA) has granted approval for anbenitamab, a HER2 bispecific antibody...
Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design
Lynk Pharmaceuticals Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted clearance...
CF PharmTech’s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease
CF PharmTech Inc. (HKG: 2652) announced that China’s National Medical Products Administration (NMPA) has granted...
Peijia Medical Secures Exclusive China Distribution Rights for B. Braun’s SeQuent Please CIS Intracranial Drug-Coated Balloon
Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG...
Basecare Medical Secures NMPA Category III Approval for Gems Oocyte Retrieval Solution in China’s IVF Market
Basecare Medical Device Co., Ltd. (HKG: 2170), a specialist in high-throughput sequencing-based assisted reproduction technologies,...
Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of Biologics License Applications (BLAs)...
Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement
Hanmi Pharm. Co., Ltd. (“Hanmi”) announced a strategic global licensing agreement with Eli Lilly (NYSE:...
Henlius Biotech’s Perjeta Biosimilar HLX11 (Poherdy) Secures NMPA Approval for HER2-Positive Breast Cancer in China
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the National Medical Products Administration (NMPA) has...
True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations
Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture...
Chengdu Kanghua Initiates Phase II Trial for RSV mRNA Vaccine Through NanoRibo Acquisition in China’s Untapped Market
Chengdu Kanghua Biological Products Co., Ltd. (SHE: 300841) announced the initiation of a Phase II...
AbbVie’s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment
AbbVie (NYSE: ABBV) announced that the European Commission (EC) has granted an expanded marketing authorization...